- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
December 26, 2013 (Healio) - Researchers from Italy have developed a novel method for estimating insulin sensitivity in patients with type 1 diabetes on sensor-augmented insulin pump therapy, according to data.
Minimally invasive continuous glucose monitoring (CGM) devices can measure interstitial glucose concentrations in continuous time for up to several days, according to Michele
November 1, 2013 (Drug Store News) -- The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.
Novo Nordisk announced the FDA approval of Novolog FlexTouch (insulin aspart [rDNA origin]) and Levemir FlexTouch (insulin detemir [rDNA origin]).
February 28, 2013 (Insulet Corporation) — Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod Insulin Management System, today announced financial results for the fourth quarter and full year ended December 31, 2012.
Fourth Quarter Results
Fourth quarter 2012 revenue increased 23% to $57.8 million, compared to $47.2 million in the fourth quarter of 2011. Gross profit for the fourth quarter of 2012 improved by 26% to $25.3 million, as compar
July 29, 2009 (Newswise) - The Centers for Disease Control and Prevention (CDC) this week held an inaugural conference on obesity prevention and control. The CDCs Division of Nutrition, Physical Activity, and Obesity convened in Washington, D.C. to chart ways to improve access to healthy places, discuss opportunities for obesity prevention, and plan physical education standards in schools through federal policy.Obesity is a risk factor for a number of chronic diseases, including diabetes, heart problems, osteoarthriti
Elron Group Company Medingo Receives Formal FDA Clearance to Market Its Insulin Micropump in the United States
July 28, 2009 (BusinessWire) - Elron Electronic Industries Ltd. (NASDAQ & TASE: ELRN) announced today, that further to it previous announcement on July 28, 2009, Medingo Ltd., a group company held 92% by Elron and its subsidiary, RDC Rafael Development Corporation Ltd., has received formal clearance from the Food and Drug Administration ("FDA"), to market its Solo MicroPump Insulin Delivery System in the United States.Medingo intends to introduce the Solo
Surveys Find Adults with Type 2 Diabetes Are More Willing to Take Action to Achieve A1C Targets Quicker than Physicians and Other Medical Professionals Perceive
FDA Votes to Change Jardiance Label to Show Reduction in Heart-Related Deaths
Low Carb vs. High Carb II – My Diabetes Diet Battle Continued